@article{DiehlSchmidLicataGoldhardtetal.2019,
  author    = {Diehl-Schmid, Janine and Licata, Abigail and Goldhardt, Oliver and F{\"o}rstl, Hans and Yakushew, Igor and Otto, Markus and Anderl-Straub, Sarah and Beer, Ambros and Ludolph, Albert Christian and Landwehrmeyer, Georg Bernhard and Levin, Johannes and Danek, Adrian and Fliessbach, Klaus and Spottke, Annika and Fassbender, Klaus and Lyros, Epameinondas and Prudlo, Johannes and Krause, Bernd Joachim and Volk, Alexander and Edbauer, Dieter and Schroeter, Matthias Leopold and Drzezga, Alexander and Kornhuber, Johannes and Lauer, Martin and Grimmer, Timo},
  title     = {FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations},
  series = {Translational Psychiatry},
  volume    = {9},
  journal   = {Translational Psychiatry},
  organization    = {FTLDc Study Group},
  doi       = {10.1038/s41398-019-0381-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-225308},
  year      = {2019},
  abstract  = {C9ORF72 mutations are the most common cause of familial frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). MRI studies have investigated structural changes in C9ORF72-associated FTLD (C9FTLD) and provided first insights about a prominent involvement of the thalamus and the cerebellum. Our multicenter, 18F-fluorodeoxyglucose positron-emission tomography study of 22 mutation carriers with FTLD, 22 matched non-carriers with FTLD, and 23 cognitively healthy controls provided valuable insights into functional changes in C9FTLD: compared to non-carriers, mutation carriers showed a significant reduction of glucose metabolism in both thalami, underscoring the key role of the thalamus in C9FTLD. Thalamic metabolism did not correlate with disease severity, duration of disease, or the presence of psychotic symptoms. Against our expectations we could not demonstrate a cerebellar hypometabolism in carriers or non-carriers. Future imaging and neuropathological studies in large patient cohorts are required to further elucidate the central role of the thalamus in C9FTLD.},
  language  = {en}
}
@article{WesterKellerSchotteliusetal.2015,
  author    = {Wester, Hans J{\"u}rgen and Keller, Ulrich and Schottelius, Margret and Beer, Ambros and Philipp-Abbrederis, Kathrin and Hoffmann, Frauke and Šimeček, Jakub and Gerngross, Carlos and Lassmann, Michael and Herrmann, Ken and Pellegata, Natalia and Rudelius, Martina and Kessler, Horst and Schwaiger, Markus},
  title     = {Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging},
  series = {Theranostics},
  volume    = {5},
  journal   = {Theranostics},
  number    = {6},
  doi       = {10.7150/thno.11251},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-144537},
  pages     = {618-630},
  year      = {2015},
  abstract  = {Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.},
  language  = {en}
}